nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—RRM1—Synthesis and interconversion of nucleotide di- and triphosphates—NME2—ovarian cancer	0.0248	0.104	CbGpPWpGaD
Fludarabine—RRM1—Nucleotide Metabolism—NME2—ovarian cancer	0.0237	0.0995	CbGpPWpGaD
Fludarabine—POLA1—Nucleotide Metabolism—NME2—ovarian cancer	0.0134	0.0561	CbGpPWpGaD
Fludarabine—POLA1—myometrium—ovarian cancer	0.00932	0.043	CbGeAlD
Fludarabine—RRM1—Nucleotide metabolism—NME2—ovarian cancer	0.00766	0.0322	CbGpPWpGaD
Fludarabine—RRM1—myometrium—ovarian cancer	0.0074	0.0341	CbGeAlD
Fludarabine—SLC28A3—bone marrow—ovarian cancer	0.0073	0.0337	CbGeAlD
Fludarabine—POLA1—uterine cervix—ovarian cancer	0.00725	0.0335	CbGeAlD
Fludarabine—SLC28A3—female gonad—ovarian cancer	0.00704	0.0325	CbGeAlD
Fludarabine—POLA1—decidua—ovarian cancer	0.00691	0.0319	CbGeAlD
Fludarabine—POLA1—Vinblastine—Vinorelbine—ovarian cancer	0.00675	0.675	CbGdCrCtD
Fludarabine—POLA1—endometrium—ovarian cancer	0.00656	0.0303	CbGeAlD
Fludarabine—SLC29A1—myometrium—ovarian cancer	0.00602	0.0278	CbGeAlD
Fludarabine—Cladribine—NR5A1—ovarian cancer	0.00593	0.704	CrCbGaD
Fludarabine—DCK—Nucleotide metabolism—NME2—ovarian cancer	0.0059	0.0247	CbGpPWpGaD
Fludarabine—RRM1—uterine cervix—ovarian cancer	0.00576	0.0266	CbGeAlD
Fludarabine—DCK—myometrium—ovarian cancer	0.00575	0.0265	CbGeAlD
Fludarabine—DCK—embryo—ovarian cancer	0.00553	0.0255	CbGeAlD
Fludarabine—RRM1—decidua—ovarian cancer	0.00548	0.0253	CbGeAlD
Fludarabine—RRM1—endometrium—ovarian cancer	0.00521	0.024	CbGeAlD
Fludarabine—POLA1—bone marrow—ovarian cancer	0.00513	0.0237	CbGeAlD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00495	0.0208	CbGpPWpGaD
Fludarabine—POLA1—female gonad—ovarian cancer	0.00494	0.0228	CbGeAlD
Fludarabine—POLA1—vagina—ovarian cancer	0.00491	0.0227	CbGeAlD
Fludarabine—RRM1—gonad—ovarian cancer	0.00483	0.0223	CbGeAlD
Fludarabine—POLA1—Inhibition of replication initiation of damaged DNA by RB1/E2F1—PPP2R1A—ovarian cancer	0.0048	0.0201	CbGpPWpGaD
Fludarabine—RRM1—uterus—ovarian cancer	0.0048	0.0221	CbGeAlD
Fludarabine—SLC29A1—uterine cervix—ovarian cancer	0.00468	0.0216	CbGeAlD
Fludarabine—DCK—uterine cervix—ovarian cancer	0.00447	0.0206	CbGeAlD
Fludarabine—SLC29A1—decidua—ovarian cancer	0.00446	0.0206	CbGeAlD
Fludarabine—POLA1—Chromosome Maintenance—RSF1—ovarian cancer	0.00441	0.0185	CbGpPWpGaD
Fludarabine—POLA1—testis—ovarian cancer	0.00439	0.0202	CbGeAlD
Fludarabine—RRM1—female reproductive system—ovarian cancer	0.00431	0.0199	CbGeAlD
Fludarabine—DCK—decidua—ovarian cancer	0.00426	0.0197	CbGeAlD
Fludarabine—SLC29A1—endometrium—ovarian cancer	0.00423	0.0195	CbGeAlD
Fludarabine—RRM1—E2F transcription factor network—RBL2—ovarian cancer	0.00418	0.0175	CbGpPWpGaD
Fludarabine—RRM1—bone marrow—ovarian cancer	0.00407	0.0188	CbGeAlD
Fludarabine—DCK—endometrium—ovarian cancer	0.00404	0.0187	CbGeAlD
Fludarabine—SLC29A1—gonad—ovarian cancer	0.00393	0.0181	CbGeAlD
Fludarabine—RRM1—female gonad—ovarian cancer	0.00392	0.0181	CbGeAlD
Fludarabine—SLC29A1—uterus—ovarian cancer	0.0039	0.018	CbGeAlD
Fludarabine—RRM1—vagina—ovarian cancer	0.0039	0.018	CbGeAlD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00381	0.016	CbGpPWpGaD
Fludarabine—DCK—gonad—ovarian cancer	0.00375	0.0173	CbGeAlD
Fludarabine—DCK—uterus—ovarian cancer	0.00373	0.0172	CbGeAlD
Fludarabine—SLC29A1—female reproductive system—ovarian cancer	0.00351	0.0162	CbGeAlD
Fludarabine—RRM1—testis—ovarian cancer	0.00348	0.0161	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.00346	0.0145	CbGpPWpGaD
Fludarabine—DCK—Pyrimidine metabolism—TYMS—ovarian cancer	0.00343	0.0144	CbGpPWpGaD
Fludarabine—POLA1—G1/S-Specific Transcription—CCNE1—ovarian cancer	0.00337	0.0142	CbGpPWpGaD
Fludarabine—DCK—female reproductive system—ovarian cancer	0.00335	0.0155	CbGeAlD
Fludarabine—POLA1—G1/S-Specific Transcription—TYMS—ovarian cancer	0.00331	0.0139	CbGpPWpGaD
Fludarabine—SLC29A1—bone marrow—ovarian cancer	0.00331	0.0153	CbGeAlD
Fludarabine—SLC29A1—female gonad—ovarian cancer	0.00319	0.0147	CbGeAlD
Fludarabine—POLA1—lymph node—ovarian cancer	0.00318	0.0147	CbGeAlD
Fludarabine—SLC29A1—vagina—ovarian cancer	0.00317	0.0146	CbGeAlD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.00316	0.0133	CbGpPWpGaD
Fludarabine—DCK—bone marrow—ovarian cancer	0.00316	0.0146	CbGeAlD
Fludarabine—DCK—female gonad—ovarian cancer	0.00305	0.0141	CbGeAlD
Fludarabine—DCK—vagina—ovarian cancer	0.00303	0.014	CbGeAlD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.00296	0.0124	CbGpPWpGaD
Fludarabine—SLC29A1—testis—ovarian cancer	0.00283	0.0131	CbGeAlD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00279	0.0117	CbGpPWpGaD
Fludarabine—DCK—testis—ovarian cancer	0.0027	0.0125	CbGeAlD
Fludarabine—RRM1—lymph node—ovarian cancer	0.00252	0.0116	CbGeAlD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00242	0.0101	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00241	0.0101	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—RBL2—ovarian cancer	0.00235	0.00988	CbGpPWpGaD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—PPP2R1A—ovarian cancer	0.00214	0.00897	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—BRCA1—ovarian cancer	0.00213	0.00894	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—AKT1—ovarian cancer	0.00213	0.252	CrCbGaD
Fludarabine—SLC29A1—lymph node—ovarian cancer	0.00205	0.00947	CbGeAlD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—CCNE1—ovarian cancer	0.00198	0.00833	CbGpPWpGaD
Fludarabine—DCK—lymph node—ovarian cancer	0.00196	0.00905	CbGeAlD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—TYMS—ovarian cancer	0.00195	0.00818	CbGpPWpGaD
Fludarabine—POLA1—Extension of Telomeres—TERT—ovarian cancer	0.00188	0.0079	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CCNE1—ovarian cancer	0.00187	0.00783	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00186	0.0078	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—TYMS—ovarian cancer	0.00183	0.00769	CbGpPWpGaD
Fludarabine—RRM1—Nucleotide metabolism—TYMS—ovarian cancer	0.00174	0.00729	CbGpPWpGaD
Fludarabine—DCK—Doxorubicin—Epirubicin—ovarian cancer	0.00169	0.169	CbGdCrCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.00167	0.00699	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.00162	0.00681	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00159	0.00668	CbGpPWpGaD
Fludarabine—DCK—Epirubicin—Doxorubicin—ovarian cancer	0.00156	0.156	CbGdCrCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.00144	0.00604	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00136	0.00571	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00136	0.0057	CbGpPWpGaD
Fludarabine—DCK—Nucleotide metabolism—TYMS—ovarian cancer	0.00134	0.00561	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.00125	0.00524	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00123	0.00514	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—BRCA1—ovarian cancer	0.0012	0.00504	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.00115	0.00484	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—ovarian cancer	0.00115	0.00481	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—SKP2—ovarian cancer	0.00114	0.00477	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—RSF1—ovarian cancer	0.00112	0.0047	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.00109	0.00458	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.00109	0.00456	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.00105	0.00442	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CCNE1—ovarian cancer	0.00105	0.00441	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.00105	0.0044	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—ovarian cancer	0.00105	0.0044	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.00105	0.00439	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—TYMS—ovarian cancer	0.00103	0.00433	CbGpPWpGaD
Fludarabine—POLA1—S Phase—SKP2—ovarian cancer	0.00103	0.00433	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000987	0.00414	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDKN1B—ovarian cancer	0.000967	0.00406	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.000958	0.00402	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.000914	0.00383	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.000897	0.00377	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000893	0.00375	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000865	0.00363	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000865	0.00363	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—TERT—ovarian cancer	0.000853	0.00358	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000849	0.00356	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000841	0.00353	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000828	0.00347	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—PPP2R1A—ovarian cancer	0.000822	0.00345	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000814	0.00342	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.00081	0.0034	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000802	0.00337	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.000783	0.00328	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000781	0.00328	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PPP1CC—ovarian cancer	0.000769	0.00323	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—CCNE1—ovarian cancer	0.000763	0.0032	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—TYMS—ovarian cancer	0.000749	0.00314	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—MYC—ovarian cancer	0.00074	0.00311	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.000734	0.00308	CbGpPWpGaD
Fludarabine—POLA1—Chromosome Maintenance—TERT—ovarian cancer	0.000711	0.00298	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—NME2—ovarian cancer	0.000696	0.00292	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCNE1—ovarian cancer	0.000693	0.00291	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.000692	0.00291	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000659	0.00277	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000649	0.00272	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000647	0.00272	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000643	0.0027	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.000643	0.0027	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.000631	0.00265	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000623	0.00262	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000617	0.00259	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000617	0.00259	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000593	0.00249	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—RAD51C—ovarian cancer	0.000588	0.00247	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.000575	0.00241	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000556	0.00233	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.000552	0.00232	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CDKN1B—ovarian cancer	0.000545	0.00229	CbGpPWpGaD
Fludarabine—DCK—Metabolism—NME2—ovarian cancer	0.000536	0.00225	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000533	0.00224	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000528	0.00222	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000528	0.00221	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PPP1CC—ovarian cancer	0.000514	0.00216	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000503	0.00211	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000495	0.00208	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000487	0.00204	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000487	0.00204	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000484	0.00203	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000478	0.00201	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000474	0.00199	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—RBL2—ovarian cancer	0.000472	0.00198	CbGpPWpGaD
Fludarabine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000467	0.000888	CcSEcCtD
Fludarabine—Asthenia—Melphalan—ovarian cancer	0.000466	0.000884	CcSEcCtD
Fludarabine—Pruritus—Melphalan—ovarian cancer	0.000459	0.000872	CcSEcCtD
Fludarabine—Haemoglobin—Docetaxel—ovarian cancer	0.000457	0.000869	CcSEcCtD
Fludarabine—Hepatic failure—Doxorubicin—ovarian cancer	0.000457	0.000868	CcSEcCtD
Fludarabine—Haemorrhage—Docetaxel—ovarian cancer	0.000455	0.000864	CcSEcCtD
Fludarabine—Cardiac failure—Epirubicin—ovarian cancer	0.000455	0.000863	CcSEcCtD
Fludarabine—Diarrhoea—Topotecan—ovarian cancer	0.000454	0.000861	CcSEcCtD
Fludarabine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000453	0.00086	CcSEcCtD
Fludarabine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000453	0.00086	CcSEcCtD
Fludarabine—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000453	0.00086	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000452	0.0019	CbGpPWpGaD
Fludarabine—Pharyngitis—Docetaxel—ovarian cancer	0.000452	0.000858	CcSEcCtD
Fludarabine—RRM1—Metabolism—CYTB—ovarian cancer	0.000449	0.00188	CbGpPWpGaD
Fludarabine—Body temperature increased—Vinorelbine—ovarian cancer	0.000448	0.000851	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000448	0.00188	CbGpPWpGaD
Fludarabine—Diarrhoea—Melphalan—ovarian cancer	0.000444	0.000843	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.000444	0.000843	CcSEcCtD
Fludarabine—Nausea—Chlorambucil—ovarian cancer	0.000442	0.00084	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000439	0.00184	CbGpPWpGaD
Fludarabine—Visual impairment—Docetaxel—ovarian cancer	0.000439	0.000833	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—CDKN1B—ovarian cancer	0.000438	0.00184	CbGpPWpGaD
Fludarabine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000434	0.000824	CcSEcCtD
Fludarabine—Anaemia—Paclitaxel—ovarian cancer	0.000432	0.00082	CcSEcCtD
Fludarabine—Erythema multiforme—Docetaxel—ovarian cancer	0.00043	0.000817	CcSEcCtD
Fludarabine—Agitation—Paclitaxel—ovarian cancer	0.00043	0.000816	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000428	0.00179	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000423	0.00178	CbGpPWpGaD
Fludarabine—Vomiting—Topotecan—ovarian cancer	0.000422	0.0008	CcSEcCtD
Fludarabine—Malaise—Paclitaxel—ovarian cancer	0.000421	0.0008	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000421	0.00177	CbGpPWpGaD
Fludarabine—Cardiac failure—Doxorubicin—ovarian cancer	0.000421	0.000799	CcSEcCtD
Fludarabine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000419	0.000796	CcSEcCtD
Fludarabine—Leukopenia—Paclitaxel—ovarian cancer	0.000418	0.000795	CcSEcCtD
Fludarabine—Rash—Topotecan—ovarian cancer	0.000418	0.000794	CcSEcCtD
Fludarabine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000418	0.000793	CcSEcCtD
Fludarabine—Dermatitis—Topotecan—ovarian cancer	0.000418	0.000793	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—MYC—ovarian cancer	0.000417	0.00175	CbGpPWpGaD
Fludarabine—Headache—Topotecan—ovarian cancer	0.000415	0.000789	CcSEcCtD
Fludarabine—Vomiting—Melphalan—ovarian cancer	0.000413	0.000784	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000413	0.00173	CbGpPWpGaD
Fludarabine—Dehydration—Epirubicin—ovarian cancer	0.000413	0.000784	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.000412	0.00173	CbGpPWpGaD
Fludarabine—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000411	0.00078	CcSEcCtD
Fludarabine—POLA1—DNA Replication—CDKN1B—ovarian cancer	0.000411	0.00172	CbGpPWpGaD
Fludarabine—Liver function test abnormal—Epirubicin—ovarian cancer	0.00041	0.000778	CcSEcCtD
Fludarabine—Rash—Melphalan—ovarian cancer	0.000409	0.000777	CcSEcCtD
Fludarabine—Dermatitis—Melphalan—ovarian cancer	0.000409	0.000777	CcSEcCtD
Fludarabine—Chills—Docetaxel—ovarian cancer	0.000408	0.000775	CcSEcCtD
Fludarabine—Cough—Paclitaxel—ovarian cancer	0.000408	0.000775	CcSEcCtD
Fludarabine—Asthenia—Vinorelbine—ovarian cancer	0.000407	0.000773	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000407	0.00171	CbGpPWpGaD
Fludarabine—Arrhythmia—Docetaxel—ovarian cancer	0.000407	0.000772	CcSEcCtD
Fludarabine—Convulsion—Paclitaxel—ovarian cancer	0.000405	0.000769	CcSEcCtD
Fludarabine—Alopecia—Docetaxel—ovarian cancer	0.000402	0.000764	CcSEcCtD
Fludarabine—Pruritus—Vinorelbine—ovarian cancer	0.000401	0.000762	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.0004	0.000759	CcSEcCtD
Fludarabine—Myalgia—Paclitaxel—ovarian cancer	0.000398	0.000756	CcSEcCtD
Fludarabine—Arthralgia—Paclitaxel—ovarian cancer	0.000398	0.000756	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000398	0.00167	CbGpPWpGaD
Fludarabine—Malnutrition—Docetaxel—ovarian cancer	0.000396	0.000752	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—CDKN1B—ovarian cancer	0.000395	0.00166	CbGpPWpGaD
Fludarabine—Nausea—Topotecan—ovarian cancer	0.000394	0.000748	CcSEcCtD
Fludarabine—Discomfort—Paclitaxel—ovarian cancer	0.000393	0.000747	CcSEcCtD
Fludarabine—RRM1—Metabolism—BRIP1—ovarian cancer	0.000392	0.00165	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPP1CC—ovarian cancer	0.000392	0.00165	CbGpPWpGaD
Fludarabine—Diarrhoea—Vinorelbine—ovarian cancer	0.000388	0.000737	CcSEcCtD
Fludarabine—Nausea—Melphalan—ovarian cancer	0.000386	0.000732	CcSEcCtD
Fludarabine—Confusional state—Paclitaxel—ovarian cancer	0.000385	0.00073	CcSEcCtD
Fludarabine—Dysphagia—Epirubicin—ovarian cancer	0.000384	0.000728	CcSEcCtD
Fludarabine—Dehydration—Doxorubicin—ovarian cancer	0.000382	0.000725	CcSEcCtD
Fludarabine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000381	0.000724	CcSEcCtD
Fludarabine—Oedema—Paclitaxel—ovarian cancer	0.000381	0.000724	CcSEcCtD
Fludarabine—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000379	0.00072	CcSEcCtD
Fludarabine—Infection—Paclitaxel—ovarian cancer	0.000379	0.00072	CcSEcCtD
Fludarabine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000374	0.00071	CcSEcCtD
Fludarabine—Angina pectoris—Epirubicin—ovarian cancer	0.000374	0.000709	CcSEcCtD
Fludarabine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000373	0.000709	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000373	0.00156	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000371	0.00156	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—ABCB1—ovarian cancer	0.000371	0.0441	CrCbGaD
Fludarabine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.00037	0.000702	CcSEcCtD
Fludarabine—Bronchitis—Epirubicin—ovarian cancer	0.000369	0.0007	CcSEcCtD
Fludarabine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000369	0.0007	CcSEcCtD
Fludarabine—Anaemia—Docetaxel—ovarian cancer	0.000366	0.000695	CcSEcCtD
Fludarabine—Pancytopenia—Epirubicin—ovarian cancer	0.000364	0.000692	CcSEcCtD
Fludarabine—Anorexia—Paclitaxel—ovarian cancer	0.000364	0.000691	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000362	0.00152	CbGpPWpGaD
Fludarabine—Vomiting—Vinorelbine—ovarian cancer	0.000361	0.000685	CcSEcCtD
Fludarabine—POLA1—S Phase—CDKN1B—ovarian cancer	0.000359	0.00151	CbGpPWpGaD
Fludarabine—Neutropenia—Epirubicin—ovarian cancer	0.000359	0.000681	CcSEcCtD
Fludarabine—Dysuria—Epirubicin—ovarian cancer	0.000359	0.000681	CcSEcCtD
Fludarabine—Rash—Vinorelbine—ovarian cancer	0.000358	0.000679	CcSEcCtD
Fludarabine—Dermatitis—Vinorelbine—ovarian cancer	0.000357	0.000678	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000356	0.000677	CcSEcCtD
Fludarabine—Headache—Vinorelbine—ovarian cancer	0.000355	0.000675	CcSEcCtD
Fludarabine—Dysphagia—Doxorubicin—ovarian cancer	0.000355	0.000674	CcSEcCtD
Fludarabine—Leukopenia—Docetaxel—ovarian cancer	0.000355	0.000673	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000353	0.00148	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000351	0.00147	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000351	0.00147	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000348	0.00066	CcSEcCtD
Fludarabine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000346	0.000657	CcSEcCtD
Fludarabine—Cough—Docetaxel—ovarian cancer	0.000346	0.000657	CcSEcCtD
Fludarabine—Angina pectoris—Doxorubicin—ovarian cancer	0.000346	0.000656	CcSEcCtD
Fludarabine—DCK—Metabolism—CYTB—ovarian cancer	0.000345	0.00145	CbGpPWpGaD
Fludarabine—Pneumonia—Epirubicin—ovarian cancer	0.000344	0.000653	CcSEcCtD
Fludarabine—Convulsion—Docetaxel—ovarian cancer	0.000343	0.000652	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000343	0.00144	CbGpPWpGaD
Fludarabine—Paraesthesia—Paclitaxel—ovarian cancer	0.000343	0.00065	CcSEcCtD
Fludarabine—POLA1—S Phase—CCND1—ovarian cancer	0.000342	0.00144	CbGpPWpGaD
Fludarabine—Bronchitis—Doxorubicin—ovarian cancer	0.000341	0.000648	CcSEcCtD
Fludarabine—Dyspnoea—Paclitaxel—ovarian cancer	0.00034	0.000646	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PPP2R1A—ovarian cancer	0.000339	0.00142	CbGpPWpGaD
Fludarabine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000339	0.000644	CcSEcCtD
Fludarabine—Myalgia—Docetaxel—ovarian cancer	0.000337	0.000641	CcSEcCtD
Fludarabine—Arthralgia—Docetaxel—ovarian cancer	0.000337	0.000641	CcSEcCtD
Fludarabine—Pancytopenia—Doxorubicin—ovarian cancer	0.000337	0.00064	CcSEcCtD
Fludarabine—Nausea—Vinorelbine—ovarian cancer	0.000337	0.00064	CcSEcCtD
Fludarabine—Renal failure—Epirubicin—ovarian cancer	0.000336	0.000638	CcSEcCtD
Fludarabine—Dyspepsia—Paclitaxel—ovarian cancer	0.000336	0.000638	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000336	0.00141	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000335	0.00141	CbGpPWpGaD
Fludarabine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000335	0.000637	CcSEcCtD
Fludarabine—Stomatitis—Epirubicin—ovarian cancer	0.000333	0.000633	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000333	0.0014	CbGpPWpGaD
Fludarabine—Urinary tract infection—Epirubicin—ovarian cancer	0.000332	0.000631	CcSEcCtD
Fludarabine—Neutropenia—Doxorubicin—ovarian cancer	0.000332	0.00063	CcSEcCtD
Fludarabine—Dysuria—Doxorubicin—ovarian cancer	0.000332	0.00063	CcSEcCtD
Fludarabine—Decreased appetite—Paclitaxel—ovarian cancer	0.000332	0.00063	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.00033	0.000626	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000329	0.000625	CcSEcCtD
Fludarabine—Fatigue—Paclitaxel—ovarian cancer	0.000329	0.000625	CcSEcCtD
Fludarabine—Pain—Paclitaxel—ovarian cancer	0.000326	0.000619	CcSEcCtD
Fludarabine—Constipation—Paclitaxel—ovarian cancer	0.000326	0.000619	CcSEcCtD
Fludarabine—Haematuria—Epirubicin—ovarian cancer	0.000326	0.000619	CcSEcCtD
Fludarabine—Confusional state—Docetaxel—ovarian cancer	0.000326	0.000619	CcSEcCtD
Fludarabine—Oedema—Docetaxel—ovarian cancer	0.000323	0.000614	CcSEcCtD
Fludarabine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000323	0.000614	CcSEcCtD
Fludarabine—Epistaxis—Epirubicin—ovarian cancer	0.000323	0.000612	CcSEcCtD
Fludarabine—Infection—Docetaxel—ovarian cancer	0.000321	0.00061	CcSEcCtD
Fludarabine—Sinusitis—Epirubicin—ovarian cancer	0.000321	0.000609	CcSEcCtD
Fludarabine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00032	0.000608	CcSEcCtD
Fludarabine—Pneumonia—Doxorubicin—ovarian cancer	0.000318	0.000604	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000318	0.00133	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MLH1—ovarian cancer	0.000318	0.00133	CbGpPWpGaD
Fludarabine—Nervous system disorder—Docetaxel—ovarian cancer	0.000317	0.000602	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000317	0.00133	CbGpPWpGaD
Fludarabine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000317	0.000601	CcSEcCtD
Fludarabine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000314	0.000597	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—SKP2—ovarian cancer	0.000314	0.00132	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000314	0.00132	CbGpPWpGaD
Fludarabine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000314	0.000596	CcSEcCtD
Fludarabine—Renal failure—Doxorubicin—ovarian cancer	0.000311	0.000591	CcSEcCtD
Fludarabine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00031	0.000589	CcSEcCtD
Fludarabine—Haemoglobin—Epirubicin—ovarian cancer	0.000309	0.000586	CcSEcCtD
Fludarabine—Stomatitis—Doxorubicin—ovarian cancer	0.000308	0.000586	CcSEcCtD
Fludarabine—Anorexia—Docetaxel—ovarian cancer	0.000308	0.000585	CcSEcCtD
Fludarabine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000308	0.000584	CcSEcCtD
Fludarabine—Haemorrhage—Epirubicin—ovarian cancer	0.000307	0.000583	CcSEcCtD
Fludarabine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000305	0.00058	CcSEcCtD
Fludarabine—Pharyngitis—Epirubicin—ovarian cancer	0.000305	0.000579	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—MYC—ovarian cancer	0.000303	0.00127	CbGpPWpGaD
Fludarabine—DCK—Metabolism—BRIP1—ovarian cancer	0.000302	0.00127	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPP1CC—ovarian cancer	0.000302	0.00127	CbGpPWpGaD
Fludarabine—Haematuria—Doxorubicin—ovarian cancer	0.000302	0.000573	CcSEcCtD
Fludarabine—Body temperature increased—Paclitaxel—ovarian cancer	0.000302	0.000573	CcSEcCtD
Fludarabine—Epistaxis—Doxorubicin—ovarian cancer	0.000298	0.000567	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000298	0.00125	CbGpPWpGaD
Fludarabine—Sinusitis—Doxorubicin—ovarian cancer	0.000297	0.000564	CcSEcCtD
Fludarabine—Visual impairment—Epirubicin—ovarian cancer	0.000296	0.000562	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000295	0.000559	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000291	0.00122	CbGpPWpGaD
Fludarabine—Paraesthesia—Docetaxel—ovarian cancer	0.00029	0.000551	CcSEcCtD
Fludarabine—Erythema multiforme—Epirubicin—ovarian cancer	0.00029	0.000551	CcSEcCtD
Fludarabine—Dyspnoea—Docetaxel—ovarian cancer	0.000288	0.000547	CcSEcCtD
Fludarabine—Haemoglobin—Doxorubicin—ovarian cancer	0.000285	0.000542	CcSEcCtD
Fludarabine—Dyspepsia—Docetaxel—ovarian cancer	0.000285	0.00054	CcSEcCtD
Fludarabine—Haemorrhage—Doxorubicin—ovarian cancer	0.000284	0.000539	CcSEcCtD
Fludarabine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000283	0.000537	CcSEcCtD
Fludarabine—Pharyngitis—Doxorubicin—ovarian cancer	0.000282	0.000535	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.000282	0.00118	CbGpPWpGaD
Fludarabine—Decreased appetite—Docetaxel—ovarian cancer	0.000281	0.000534	CcSEcCtD
Fludarabine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000281	0.000534	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000279	0.00053	CcSEcCtD
Fludarabine—Fatigue—Docetaxel—ovarian cancer	0.000279	0.000529	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—BIRC5—ovarian cancer	0.000278	0.00117	CbGpPWpGaD
Fludarabine—Constipation—Docetaxel—ovarian cancer	0.000276	0.000525	CcSEcCtD
Fludarabine—Pain—Docetaxel—ovarian cancer	0.000276	0.000525	CcSEcCtD
Fludarabine—Chills—Epirubicin—ovarian cancer	0.000275	0.000523	CcSEcCtD
Fludarabine—POLA1—S Phase—MYC—ovarian cancer	0.000275	0.00115	CbGpPWpGaD
Fludarabine—Arrhythmia—Epirubicin—ovarian cancer	0.000274	0.000521	CcSEcCtD
Fludarabine—Visual impairment—Doxorubicin—ovarian cancer	0.000274	0.00052	CcSEcCtD
Fludarabine—Asthenia—Paclitaxel—ovarian cancer	0.000274	0.00052	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000273	0.00114	CbGpPWpGaD
Fludarabine—Alopecia—Epirubicin—ovarian cancer	0.000271	0.000515	CcSEcCtD
Fludarabine—Pruritus—Paclitaxel—ovarian cancer	0.00027	0.000513	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000269	0.00113	CbGpPWpGaD
Fludarabine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000269	0.00051	CcSEcCtD
Fludarabine—Malnutrition—Epirubicin—ovarian cancer	0.000267	0.000507	CcSEcCtD
Fludarabine—Feeling abnormal—Docetaxel—ovarian cancer	0.000266	0.000506	CcSEcCtD
Fludarabine—RRM1—Metabolism—YAP1—ovarian cancer	0.000263	0.0011	CbGpPWpGaD
Fludarabine—Diarrhoea—Paclitaxel—ovarian cancer	0.000261	0.000496	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CHEK2—ovarian cancer	0.000257	0.00108	CbGpPWpGaD
Fludarabine—Body temperature increased—Docetaxel—ovarian cancer	0.000256	0.000485	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000255	0.00107	CbGpPWpGaD
Fludarabine—Chills—Doxorubicin—ovarian cancer	0.000255	0.000484	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000254	0.00107	CbGpPWpGaD
Fludarabine—Arrhythmia—Doxorubicin—ovarian cancer	0.000254	0.000482	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000252	0.00106	CbGpPWpGaD
Fludarabine—Alopecia—Doxorubicin—ovarian cancer	0.000251	0.000477	CcSEcCtD
Fludarabine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000248	0.000471	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000247	0.00104	CbGpPWpGaD
Fludarabine—Malnutrition—Doxorubicin—ovarian cancer	0.000247	0.00047	CcSEcCtD
Fludarabine—Anaemia—Epirubicin—ovarian cancer	0.000247	0.000469	CcSEcCtD
Fludarabine—Agitation—Epirubicin—ovarian cancer	0.000246	0.000466	CcSEcCtD
Fludarabine—Vomiting—Paclitaxel—ovarian cancer	0.000243	0.000461	CcSEcCtD
Fludarabine—Malaise—Epirubicin—ovarian cancer	0.000241	0.000458	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000241	0.00101	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CCND2—ovarian cancer	0.000241	0.00101	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—BRCA1—ovarian cancer	0.000241	0.00101	CbGpPWpGaD
Fludarabine—Rash—Paclitaxel—ovarian cancer	0.000241	0.000457	CcSEcCtD
Fludarabine—Dermatitis—Paclitaxel—ovarian cancer	0.00024	0.000456	CcSEcCtD
Fludarabine—Leukopenia—Epirubicin—ovarian cancer	0.000239	0.000454	CcSEcCtD
Fludarabine—Headache—Paclitaxel—ovarian cancer	0.000239	0.000454	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000238	0.001	CbGpPWpGaD
Fludarabine—Hypersensitivity—Docetaxel—ovarian cancer	0.000238	0.000452	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000238	0.000998	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000236	0.000989	CbGpPWpGaD
Fludarabine—Cough—Epirubicin—ovarian cancer	0.000233	0.000443	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000232	0.000975	CbGpPWpGaD
Fludarabine—Asthenia—Docetaxel—ovarian cancer	0.000232	0.000441	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000232	0.000972	CbGpPWpGaD
Fludarabine—Convulsion—Epirubicin—ovarian cancer	0.000232	0.00044	CcSEcCtD
Fludarabine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000229	0.000436	CcSEcCtD
Fludarabine—Pruritus—Docetaxel—ovarian cancer	0.000229	0.000434	CcSEcCtD
Fludarabine—Anaemia—Doxorubicin—ovarian cancer	0.000229	0.000434	CcSEcCtD
Fludarabine—Myalgia—Epirubicin—ovarian cancer	0.000227	0.000432	CcSEcCtD
Fludarabine—Arthralgia—Epirubicin—ovarian cancer	0.000227	0.000432	CcSEcCtD
Fludarabine—Agitation—Doxorubicin—ovarian cancer	0.000227	0.000431	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—PPP2R1A—ovarian cancer	0.000227	0.000953	CbGpPWpGaD
Fludarabine—Nausea—Paclitaxel—ovarian cancer	0.000227	0.00043	CcSEcCtD
Fludarabine—Discomfort—Epirubicin—ovarian cancer	0.000225	0.000427	CcSEcCtD
Fludarabine—Malaise—Doxorubicin—ovarian cancer	0.000223	0.000423	CcSEcCtD
Fludarabine—Leukopenia—Doxorubicin—ovarian cancer	0.000221	0.00042	CcSEcCtD
Fludarabine—Diarrhoea—Docetaxel—ovarian cancer	0.000221	0.00042	CcSEcCtD
Fludarabine—Confusional state—Epirubicin—ovarian cancer	0.00022	0.000418	CcSEcCtD
Fludarabine—Oedema—Epirubicin—ovarian cancer	0.000218	0.000414	CcSEcCtD
Fludarabine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000218	0.000414	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—BRCA2—ovarian cancer	0.000218	0.000913	CbGpPWpGaD
Fludarabine—Infection—Epirubicin—ovarian cancer	0.000217	0.000411	CcSEcCtD
Fludarabine—Cough—Doxorubicin—ovarian cancer	0.000216	0.00041	CcSEcCtD
Fludarabine—RRM1—Metabolism—FASN—ovarian cancer	0.000214	0.0009	CbGpPWpGaD
Fludarabine—Convulsion—Doxorubicin—ovarian cancer	0.000214	0.000407	CcSEcCtD
Fludarabine—Nervous system disorder—Epirubicin—ovarian cancer	0.000214	0.000406	CcSEcCtD
Fludarabine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000214	0.000406	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC5A5—ovarian cancer	0.000211	0.000885	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000211	0.0004	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CCNE1—ovarian cancer	0.000211	0.000885	CbGpPWpGaD
Fludarabine—Myalgia—Doxorubicin—ovarian cancer	0.00021	0.0004	CcSEcCtD
Fludarabine—Arthralgia—Doxorubicin—ovarian cancer	0.00021	0.0004	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.00021	0.000881	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—BIRC5—ovarian cancer	0.000208	0.000874	CbGpPWpGaD
Fludarabine—Discomfort—Doxorubicin—ovarian cancer	0.000208	0.000395	CcSEcCtD
Fludarabine—Anorexia—Epirubicin—ovarian cancer	0.000208	0.000395	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—TYMS—ovarian cancer	0.000207	0.000869	CbGpPWpGaD
Fludarabine—Vomiting—Docetaxel—ovarian cancer	0.000206	0.00039	CcSEcCtD
Fludarabine—Rash—Docetaxel—ovarian cancer	0.000204	0.000387	CcSEcCtD
Fludarabine—Dermatitis—Docetaxel—ovarian cancer	0.000204	0.000387	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC2A1—ovarian cancer	0.000204	0.000855	CbGpPWpGaD
Fludarabine—Confusional state—Doxorubicin—ovarian cancer	0.000203	0.000386	CcSEcCtD
Fludarabine—Headache—Docetaxel—ovarian cancer	0.000203	0.000385	CcSEcCtD
Fludarabine—DCK—Metabolism—YAP1—ovarian cancer	0.000202	0.000849	CbGpPWpGaD
Fludarabine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000202	0.000383	CcSEcCtD
Fludarabine—Oedema—Doxorubicin—ovarian cancer	0.000202	0.000383	CcSEcCtD
Fludarabine—Infection—Doxorubicin—ovarian cancer	0.0002	0.000381	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000199	0.000377	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000199	0.000833	CbGpPWpGaD
Fludarabine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000198	0.000376	CcSEcCtD
Fludarabine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000198	0.000375	CcSEcCtD
Fludarabine—Paraesthesia—Epirubicin—ovarian cancer	0.000196	0.000372	CcSEcCtD
Fludarabine—RRM1—Metabolism—CYP1B1—ovarian cancer	0.000195	0.000819	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000195	0.00037	CcSEcCtD
Fludarabine—Dyspnoea—Epirubicin—ovarian cancer	0.000194	0.000369	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000193	0.000811	CbGpPWpGaD
Fludarabine—Anorexia—Doxorubicin—ovarian cancer	0.000192	0.000365	CcSEcCtD
Fludarabine—Nausea—Docetaxel—ovarian cancer	0.000192	0.000365	CcSEcCtD
Fludarabine—Dyspepsia—Epirubicin—ovarian cancer	0.000192	0.000365	CcSEcCtD
Fludarabine—Decreased appetite—Epirubicin—ovarian cancer	0.00019	0.00036	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000189	0.000793	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000189	0.000793	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000188	0.000358	CcSEcCtD
Fludarabine—Fatigue—Epirubicin—ovarian cancer	0.000188	0.000357	CcSEcCtD
Fludarabine—Constipation—Epirubicin—ovarian cancer	0.000186	0.000354	CcSEcCtD
Fludarabine—Pain—Epirubicin—ovarian cancer	0.000186	0.000354	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—BIRC5—ovarian cancer	0.000186	0.000781	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000184	0.000349	CcSEcCtD
Fludarabine—Paraesthesia—Doxorubicin—ovarian cancer	0.000181	0.000344	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—TERT—ovarian cancer	0.00018	0.000757	CbGpPWpGaD
Fludarabine—Dyspnoea—Doxorubicin—ovarian cancer	0.00018	0.000342	CcSEcCtD
Fludarabine—Feeling abnormal—Epirubicin—ovarian cancer	0.00018	0.000341	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000178	0.000749	CbGpPWpGaD
Fludarabine—Dyspepsia—Doxorubicin—ovarian cancer	0.000178	0.000337	CcSEcCtD
Fludarabine—Decreased appetite—Doxorubicin—ovarian cancer	0.000175	0.000333	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000174	0.000331	CcSEcCtD
Fludarabine—Fatigue—Doxorubicin—ovarian cancer	0.000174	0.00033	CcSEcCtD
Fludarabine—RRM1—Metabolism—PPP2R1A—ovarian cancer	0.000173	0.000727	CbGpPWpGaD
Fludarabine—Pain—Doxorubicin—ovarian cancer	0.000173	0.000328	CcSEcCtD
Fludarabine—Constipation—Doxorubicin—ovarian cancer	0.000173	0.000328	CcSEcCtD
Fludarabine—Body temperature increased—Epirubicin—ovarian cancer	0.000172	0.000327	CcSEcCtD
Fludarabine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000166	0.000316	CcSEcCtD
Fludarabine—DCK—Metabolism—FASN—ovarian cancer	0.000165	0.000692	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000164	0.000688	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SLC5A5—ovarian cancer	0.000162	0.000681	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ABCB1—ovarian cancer	0.000161	0.000675	CbGpPWpGaD
Fludarabine—Hypersensitivity—Epirubicin—ovarian cancer	0.000161	0.000305	CcSEcCtD
Fludarabine—Body temperature increased—Doxorubicin—ovarian cancer	0.00016	0.000303	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.000159	0.000666	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—TYMS—ovarian cancer	0.000158	0.000663	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SLC2A1—ovarian cancer	0.000157	0.000658	CbGpPWpGaD
Fludarabine—Asthenia—Epirubicin—ovarian cancer	0.000156	0.000297	CcSEcCtD
Fludarabine—Pruritus—Epirubicin—ovarian cancer	0.000154	0.000293	CcSEcCtD
Fludarabine—DCK—Metabolism—CYP1B1—ovarian cancer	0.00015	0.000631	CbGpPWpGaD
Fludarabine—Diarrhoea—Epirubicin—ovarian cancer	0.000149	0.000283	CcSEcCtD
Fludarabine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000149	0.000282	CcSEcCtD
Fludarabine—Asthenia—Doxorubicin—ovarian cancer	0.000145	0.000275	CcSEcCtD
Fludarabine—Pruritus—Doxorubicin—ovarian cancer	0.000143	0.000271	CcSEcCtD
Fludarabine—Vomiting—Epirubicin—ovarian cancer	0.000139	0.000263	CcSEcCtD
Fludarabine—Diarrhoea—Doxorubicin—ovarian cancer	0.000138	0.000262	CcSEcCtD
Fludarabine—Rash—Epirubicin—ovarian cancer	0.000138	0.000261	CcSEcCtD
Fludarabine—Dermatitis—Epirubicin—ovarian cancer	0.000137	0.000261	CcSEcCtD
Fludarabine—Headache—Epirubicin—ovarian cancer	0.000137	0.000259	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000134	0.000562	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPP2R1A—ovarian cancer	0.000133	0.000559	CbGpPWpGaD
Fludarabine—Nausea—Epirubicin—ovarian cancer	0.00013	0.000246	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAPK3—ovarian cancer	0.000129	0.000539	CbGpPWpGaD
Fludarabine—Vomiting—Doxorubicin—ovarian cancer	0.000128	0.000244	CcSEcCtD
Fludarabine—RRM1—Metabolism—CAV1—ovarian cancer	0.000127	0.000534	CbGpPWpGaD
Fludarabine—Rash—Doxorubicin—ovarian cancer	0.000127	0.000242	CcSEcCtD
Fludarabine—Dermatitis—Doxorubicin—ovarian cancer	0.000127	0.000241	CcSEcCtD
Fludarabine—Headache—Doxorubicin—ovarian cancer	0.000126	0.00024	CcSEcCtD
Fludarabine—DCK—Metabolism—ABCB1—ovarian cancer	0.000124	0.000519	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAPK1—ovarian cancer	0.000122	0.000513	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	0.000122	0.000513	CbGpPWpGaD
Fludarabine—DCK—Metabolism—TYMS—ovarian cancer	0.000122	0.00051	CbGpPWpGaD
Fludarabine—Nausea—Doxorubicin—ovarian cancer	0.00012	0.000228	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND1—ovarian cancer	0.000117	0.000489	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CG—ovarian cancer	0.000116	0.000486	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN1B—ovarian cancer	0.000109	0.000459	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CCND1—ovarian cancer	0.000104	0.000437	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CD—ovarian cancer	0.000102	0.000428	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CAV1—ovarian cancer	9.79e-05	0.000411	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAPK3—ovarian cancer	9.62e-05	0.000403	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MYC—ovarian cancer	9.35e-05	0.000392	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAPK1—ovarian cancer	9.15e-05	0.000384	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CG—ovarian cancer	8.92e-05	0.000374	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CB—ovarian cancer	8.88e-05	0.000373	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAPK3—ovarian cancer	8.6e-05	0.000361	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MYC—ovarian cancer	8.36e-05	0.000351	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAPK1—ovarian cancer	8.18e-05	0.000343	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CD—ovarian cancer	7.84e-05	0.000329	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTEN—ovarian cancer	7.67e-05	0.000322	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—ovarian cancer	6.87e-05	0.000288	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CB—ovarian cancer	6.83e-05	0.000287	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTEN—ovarian cancer	5.91e-05	0.000248	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CA—ovarian cancer	5.41e-05	0.000227	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—AKT1—ovarian cancer	4.42e-05	0.000186	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CA—ovarian cancer	4.17e-05	0.000175	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AKT1—ovarian cancer	3.4e-05	0.000143	CbGpPWpGaD
